Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.35USD
280.64 KUSD
34.59 MUSD
2.10 M
About Daxor Corporation
Sector
Industry
CEO
Michael R. Feldschuh
Website
Headquarters
Oak Ridge
Founded
1970
FIGI
BBG000BHHF34
DAXOR Corporation is an innovative medical instrumentation and biotechnology company. DAXOR designed and developed the BVA-100 Blood Volume Analyzer. It is the first instrument approved by the FDA to provide rapid direct measurement of a patient's true blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. The BVA-100 is a semi-automated Blood Volume Analyzer. It is used in conjunction with a single use diagnostic kit. It is the first FDA-approved instrument to provide rapid direct measurement of a patient's blood volume.
An aggregate view of professional's ratings.
Frequently Asked Questions
The current price of DXR is 8.70 USD — it has decreased by −8.23% in the past 24 hours. Watch Daxor Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Daxor Corporation stocks are traded under the ticker DXR.
DXR stock has risen by 0.35% compared to the previous week, the month change is a 2.35% rise, over the last year Daxor Corporation has showed a −9.47% decrease.
We've gathered analysts' opinions on Daxor Corporation future price: according to them, DXR price has a max estimate of 22.00 USD and a min estimate of 22.00 USD. Watch DXR chart and read a more detailed Daxor Corporation stock forecast: see what analysts think of Daxor Corporation and suggest that you do with its stocks.
DXR stock is 8.97% volatile and has beta coefficient of −0.11. Track Daxor Corporation stock price on the chart and check out the list of the most volatile stocks — is Daxor Corporation there?
Today Daxor Corporation has the market capitalization of 42.08 M, it has decreased by −5.46% over the last week.
Yes, you can track Daxor Corporation financials in yearly and quarterly reports right on TradingView.
Daxor Corporation is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
DXR net income for the last half-year is −1.63 M USD, while the previous report showed 3.32 M USD of net income which accounts for −149.15% change. Track more Daxor Corporation financial stats to get the full picture.
Daxor Corporation dividend yield was 0.00% in 2023, and payout ratio reached 0.00%. The year before the numbers were 0.00% and 0.00% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Daxor Corporation EBITDA is 1.48 M USD, and current EBITDA margin is 0.95%. See more stats in Daxor Corporation financial statements.
Like other stocks, DXR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Daxor Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Daxor Corporation technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Daxor Corporation stock shows the sell signal. See more of Daxor Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.